Find News

Filter articles

Applied Filters

Showing 831 to 840 of 910 results

Indian court dismisses Teva’s bid to block Copaxone generic


The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Federal Circuit rejects challenge to GSK’s Avodart and Jalyn

US28-02-2014Legal developments

The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.

US district court invalidates Megace patent

Taiwan, US25-02-2014Legal developments

The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576.

Pfizer Australia faces antitrust accusations


Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.

Appeals court ruling blocks Lyrica competition until 2018


The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.

Generic KRKA to receive damages in Nexium case

UK28-01-2014Legal developments

The UK High Court has decided to award Slovenian generic pharmaceutical company KRKA damages after a preliminary injunction enforced against the company by AstraZeneca was discharged.

India considers more compulsory licences


A government-appointed panel in India is preparing to evaluate more patented drugs for local generic pharmaceutical companies to mimic, according to reports.

Novo Nordisk leaves alliance over PR campaign

South Africa23-01-2014

Pharmaceutical company Novo Nordisk has left a group of pharmaceutical companies that are unhappy with proposed drug laws in South Africa.

Actavis survives challenge to birth control pill

US21-01-2014Legal developments

On January 17, Actavis confirmed that the US District Court for the District of New Jersey found its US patent 7,704,984, which covers Lo Loestrin Fe birth control pills, to be valid and infringed by Lupin and Amneal.

Aurobindo to acquire Actavis’s European generic units

EU, India20-01-2014Mergers & acquisitions

Aurobindo’s European subsidiary is set to acquire Actavis’s commercial generic operations in seven Western European markets in a deal worth about €30 million ($40 million).

Showing 831 to 840 of 910 results